This article is more than 5 years old. Information may no longer be current.
Arthrex, Inc. signs agreement to buy Cardo Medical, Inc.'s joint arthroplasty division
Click Here to Manage Email Alerts
Cardo Medical, Inc. and Arthrex, Inc. announced that they signed an asset purchase agreement to sell all of Cardo's joint arthroplasty division, which comprises all of its hip and knee assets, to Arthrex. Cardo will file a current report on Form 8-K with the Securities and Exchange Commission (SEC) within the next 4 business days.
The boards of directors for Cardo and Arthrex have approved and adopted the agreement and the transaction contemplated thereby. A majority of Cardo's stockholders have also approved and adopted the agreement. Cardo will mail to its stockholders an information statement describing the terms of the written consent and the asset sale transaction, which mailing will occur only after the information statement has been filed and cleared with the SEC staff. The closing of the asset sale transaction will be subject to certain closing conditions, including that at least 20 calendar days have passed since Cardo mailed the definitive information statement to its stockholders.
Cardo Chairman of the Board and CEO, Andrew A. Brooks, MD, FACS, commented in a press release announcing the sale, “Arthrex is a global leader in sports medicine which stands at the pinnacle of innovation for our industry. We look forward to seeing Cardo's innovative arthroplasty products introduced to surgeons around the world through the extensive global distribution network Arthrex has built."
Reinhold Schmieding, founder and chief executive officer of Arthrex, noted, "The reconstructive joint products developed by the talented Cardo Medical team will be an exciting addition to our existing sports medicine portfolio. We are thrilled to be enhancing our own capabilities for expanding the continuum of treatment for the orthopedic and sports medicine patient."
Cardo plans to continue as a public company with its shares of common stock continuing to trade on the OTC Bulletin Board. Cardo is continuing to explore other strategic alternatives for its spine division, according to the press release.